[{"id":"c5a7f9eb-55ee-4160-bb2f-095df5c5c5cc","acronym":"JEWEL-101","url":"https://clinicaltrials.gov/study/NCT04925284","created_at":"2023-05-03T19:04:55.692Z","updated_at":"2024-07-02T16:35:06.232Z","phase":"Phase 1","brief_title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","source_id_and_acronym":"NCT04925284 - JEWEL-101","lead_sponsor":"Exelixis","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • samatatug zovodotin (XB002)"],"overall_status":"Recruiting","enrollment":" Enrollment 573","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-03"}]